1. Home
  2. For Clinicians
  3. The GeneSight® Advantage

The GeneSight® Advantage

A market-leading pharmacogenomic test

Why Choose the GeneSight test for Your Patients?

Offering the GeneSight test to your patients can provide a more personalized approach to mental health treatment. By analyzing how a patient’s genes may affect their outcomes to certain medications, the genetic insights from the GeneSight test can help healthcare providers in making more informed treatment decisions, potentially reducing the trial-and-error process.

Criteria for making pharmacogenomic calls

GeneSight Psychotropic only includes genes in the algorithm that have a variant that has a significant impact on medication outcomes, as demonstrated in multiple well-designed studies.

  • The GeneSight test incorporates information from peer-reviewed literature, the FDA, in-house research, and pharmacogenomics organizations such as CPIC
  • Analytical validity – the overall accuracy of the GeneSight Psychotropic test is 99.8%1

  • Criteria for making pharmacogenomic calls

    GeneSight Psychotropic only includes genes in the algorithm that have a variant that has a significant impact on medication outcomes, as demonstrated in multiple well-designed studies.

    • The GeneSight test incorporates information from peer-reviewed literature, the FDA, in-house research, and pharmacogenomics organizations such as CPIC
    • Analytical validity – the overall accuracy of the GeneSight Psychotropic test is 99.8%1

Weighted multi-gene approach

The GeneSight Psychotropic test uses a weighted multi-gene approach that measures multiple genomic variants for each individual and weighs them together to provide comprehensive information about how an individual’s genetic variation may impact their outcomes with certain medications.

  • Compared to single-gene approaches, the weighted multi-gene approach used by the GeneSight test has been shown to be a better predictor of:
    • antidepressant blood levels2-4
    • clinical outcomes with antidepressants4

  • Weighted multi-gene approach

    The GeneSight Psychotropic test uses a weighted multi-gene approach that measures multiple genomic variants for each individual and weighs them together to provide comprehensive information about how an individual’s genetic variation may impact their outcomes with certain medications.

    • Compared to single-gene approaches, the weighted multi-gene approach used by the GeneSight test has been shown to be a better predictor of:
      • antidepressant blood levels2-4
      • clinical outcomes with antidepressants4

Evidence

There are multiple peer-reviewed publications that support the clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test.

  • The two largest pharmacogenomic RCTs in mental health, PRIME Care (n=1944)5 and GUIDED (n=1167),6 showed significantly improved remission rates for patients with depression who had at least one prior treatment failure
  • Economic utility – patients who received GeneSight testing had ~$1,000 savings in annual medication spend, increased adherence, and reduced polypharmacy compared to treatment as usual7

  • Evidence

    There are multiple peer-reviewed publications that support the clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test.

    • The two largest pharmacogenomic RCTs in mental health, PRIME Care (n=1944)5 and GUIDED (n=1167),6 showed significantly improved remission rates for patients with depression who had at least one prior treatment failure
    • Economic utility – patients who received GeneSight testing had ~$1,000 savings in annual medication spend, increased adherence, and reduced polypharmacy compared to treatment as usual7

The GeneSight test: A best-in-class-experience

Medical affairs team

  • Complimentary report consultations for clinicians with a team of MDs, PhDs, and PharmDs
  • Complimentary report overviews for patients with genetic counselors

Easy and secure ordering process

  • Access to secure GeneSight Portal to place orders, view results, and order supplies
  • Sample collected via simple cheek swab

Educational resources

  • Numerous resources available including the Clinician Report Interpretation Resource, white papers, publications, etc.
  • Medical teams dedicated to educating clinicians on appropriate GeneSight implementation and utilization

State-of-art laboratory

  • Results typically returned within 2 days after the sample is received by our lab
  • Lab accreditations include CLIA, CAP, and NY State

Customer support

  • Customer service team to assist with any questions on the test
  • Sales representatives to help with registration and ordering

GeneSight at Home

  • Ability for patient to collect sample from home using GeneSight at Home collection kit if clinician is treating patient remotely

Affordability

  • Over 98% of patients pay $330 or less*
  • Typically, $0 out-of-pocket for patients with Medicare or Medicaid
  • Financial assistance and interest-free payment plans are available

* Based on a review of six months of past claim data for major insurance carriers across the US. Last updated 2023.

Commitment to patient privacy

  • DNA samples are destroyed within 60 days, or earlier upon patient request
  • HITRUST certified

Clinicians have ordered the GeneSight test for over 3,000,000 patients and counting

Take the next step with the GeneSight test

Take a step closer to getting the GeneSight test or registering to provide the test to your patients. We will follow up with additional information either via email or phone.

The GeneSight test must be ordered by a registered clinician. If you are a patient, caregiver or office staff who would like a clinician to be registered to administer the GeneSight test, please include their name and contact information.

If you are a current registered provider or tested patient, please contact us.

Take the Next Step - PD

  1. Step 1
  2. Step 2
  3. Step 3
Please provide us with your name



  1. Step 1
  2. Step 2
  3. Step 3
Please provide contact and clinic information
Please provide contact information

We are asking for Date of Birth for data verification purposes.










We are asking for Date of Birth for data verification purposes.

If you do not have a clinician, we have a directory of healthcare providers who are registered to order the GeneSight test. When you complete this form, we will link you to this directory, so you will have the option to view registered GeneSight providers in your area.







Your clinician who is currently managing your medication and making treatment decisions can order your GeneSight test.

If you do not have a clinician, we have a directory of healthcare providers who are registered to order the GeneSight test. When you complete this form, we will link you to this directory, so you will have the option to view registered GeneSight providers in your area.

Please provide your clinician's information
The GeneSight test must be ordered by your clinician








  1. Step 1
  2. Step 2
  3. Step 3

How can we help?
When completed, we'll follow up with more information
Please let us know how we can best help you
When completed, we'll follow up with more information

If you are a patient or a caregiver and would like to request a copy of your results, please complete the Patient Report Request form here









Contact Information

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Take the Next Step” page you agree to the possible transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be utilized for the sole purpose it was submitted for and governed by our Privacy Notice.

References: 1. Jablonski MR, King N, Wang Y, et al. Analytical validation of a psychiatric pharmacogenomic test. Personalized Medicine. 2018;15(3):189-197. doi:https://doi.org/10.2217/pme-2017-0094. 2. Shelton RC, Parikh SV, Law RA, et al. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Research. 2020;290:113017. doi:https://doi.org/10.1016/j.psychres.2020.113017. 3. Parikh SV, Law RA, Hain DT, et al. Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. Psychiatry Research. 2022;308:114354. doi:https://doi.org/10.1016/j.psychres.2021.114354. 4. Rothschild AJ, Parikh SV, Hain D, et al. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Research. 2021;296:113649. doi:https://doi.org/10.1016/j.psychres.2020.113649. 5. Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151-161. doi:https://doi.org/10.1001/jama.2022.9805. 6. Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019;111:59-67. doi:https://doi.org/10.1016/j.jpsychires.2019.01.003. 7. Winner JG, Carhart JM, Altar CA, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Current Medical Research and Opinion. 2015;31(9):1633-1643. doi:https://doi.org/10.1185/03007995.2015.1063483.

Take the next step